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Background: Polycystic ovarian syndrome (PCOS) is one of the most common reproductive disorders with strong
association with both insulin resistance and non-alcoholic fatty liver disease (NAFLD). To untangle the complex
relationship between PCOS and NAFLD, we analyzed serum biomarkers of apoptosis, some adipokines and mRNA
profiles in the visceral adipose tissue of obese patients with NAFLD who were also diagnosed with PCOS and
compared to a group with NAFLD only.
Methods: We included patients with biopsy-proven NAFLD and PCOS (N = 12) and BMI-matched biopsy-proven
NAFLD patients without PCOS (N = 12). Expression levels of individual mRNAs and soluble serum biomarkers were
compared by non-parametric Mann–Whitney test. The analysis also included Spearman rank correlation tests and
multiple regression analysis. For co-correlated genes, the factor analysis was performed.
Results: The total serum levels of apoptotic biomarker M30 were significantly elevated in PCOS patients with liver
steatosis as compared to non-PCOS NAFLD controls (P < 0.02), pointing that androgen-dependent proapoptotic
PCOS environment that may directly contribute to NAFLD progression in these patients. Similarly,
hyperandrogenism may explain the observed PCOS-specific decrease (P < 0.04) in adipose LDLR mRNA expression
that may be connected to the proneness of PCOS patients to NAFLD. The levels of mRNA encoding angiogenesis-
associated GSK-3B interacting protein ninein were also significantly increased in the adipose tissue of NAFLD
patients with PCOS (P < 0.007). Furthermore, the levels of resistin positively correlated with expression levels of LDLR
and prothrombin time (PT).
Conclusion: An androgen-dependent proapoptotic PCOS environment may directly contribute to NAFLD
progression in these patients. Hyperandrogenism may explain an observed decrease in adipose LDLR mRNA
expression. An inflammation-associated increase in the release of resistin into circulation might contribute to the
prothrombotic state observed under conditions associated with insulin resistance, including PCOS. The studies of
larger cohorts of NAFLD with and without PCOS patients are needed to further assess these potential interactions.
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Polycystic ovarian syndrome (PCOS) is one of the most
common reproductive disorders with a strong associ-
ation with insulin resistance [1]. The prevalence of
PCOS in theCommunity setting varies from 5% to 10%
of women of child-bearing age. The Rotterdam diagnos-
tic criteria for PCOS include presence of any two of the
following features: oligoovulation or anovulation, clinical
or biochemical hyperandrogenism and radiologic docu-
mentation of polycystic ovaries. [2]. According to these
criteria, the true prevalence rates for PCOS may be as
high as 18% [3].
Importantly, PCOS is related not only to the alteration
of the levels of hormones that regulate the normal devel-
opment of eggs in the ovaries, but also to disturbances
in other metabolic pathways, such as glucose and lipid
metabolisms [4]. In fact, PCOS affects only 5% of lean
women whereas it occurs in about 28% of obese women,
indicating a relationship between PCOS and obesity
[3,5]. In particular, obesity significantly worsens all meta-
bolic and reproductive outcomes of patients with PCOS
except for hirsutism [6].
Non-alcoholic fatty liver disease (NAFLD) is another
manifestation of obesity and metabolic syndrome and is
now recognized as a major cause of chronic liver disease,
affecting 25% to 30% of the U.S. population [7]. Con-
versely, in obese and overweight individuals, NAFLD
prevalence can be as high as 70% [7]. The pathological
spectrum of NAFLD ranges from simple hepatic
steatosis to more severe manifestations such as non-
alcoholic steatohepatitis (NASH), hepatic fibrosis, and
cirrhosis [8].
Both PCOS and NAFLD share crucial features of
metabolic syndrome including visceral obesity, hyperten-
sion, dyslipidemia and insulin resistance [9,10]. Insulin
resistance is observed in about 50% to 80% of PCOS pa-
tients [11] and in up to 80% of some groups of NAFLD
patients [12]. Intuitively, one would assume insulin re-
sistance to be always associated with obesity, but clinical
evidence has revealed that it exists in both lean and
obese women with PCOS [13,14]. As noted previously,
insulin resistance is also a key event linking NAFLD to
metabolic syndrome since clinical features of metabolic
syndrome, such as type 2 diabetes, hypertension,
dyslipidemia, and obesity, are commonly diagnosed in
NAFLD patients [15]. Moreover, NAFLD is now consid-
ered to be the hepatic manifestation of metabolic
syndrome [16] while PCOS may be the ovarian manifest-
ation of metabolic syndrome [10].
Although both PCOS and NAFLD progress through
the requisite steps of central obesity and insulin resist-
ance, the two disorders are not always present in the
same patient. Research on the commonalities of these
two disorders has yielded conflicting conclusions, oftenconfounded by the additional complications posed by
the concurrent presence of metabolic syndrome. Despite
these unresolved issues, it is evident that PCOS and
NAFLD share some metabolic pathways influenced by
both obesity and insulin resistance. Untangling this com-
plex relationship may provide better options for the
treatment of these diseases, as well as the prevention of
associated risk factors.
An aberrant adipokine production in visceral adipose
tissue has been implicated in both metabolic syndrome
and the pathogenesis of NAFLD/NASH [17,18]. So far,
however, there is a paucity of information on PCOS re-
lated gene expression patterns in the adipose tissue. In
this study, our aim was to analyze the mRNA profiles in
the visceral adipose tissue of obese patients with biopsy-
proven NAFLD with and without PCOS. To further sup-
port our findings, we augmented our data by protein
expression studies using serum samples collected from
the same patients at the time of liver biopsy and adipose
tissue sample collection.
Methods
Sample collection, storage and selection
A study set of 24 visceral adipose tissues (VAT) accom-
panied by serum samples was selected from existing
biobank of more than 400 archived specimens previously
collected from obese patients at the time of their bariat-
ric surgeries after informed consent and immediately
frozen with liquid nitrogen before storage at −80 C.
Thorough histories were obtained including alcohol use,
history of diabetes mellitus, hypertension, or hyperlipid-
emia (all were defined by clinical diagnosis requiring
medical therapy). Height, weight, hip, and waist mea-
surements were collected pre-surgery along with
laboratory tests included fasting glucose, serum amino-
transferases (ALT and AST) and lipid panel. Patients
with evidence of excessive alcohol use (>10 g/d), other
causes of liver disease (e.g., viral hepatitis, autoimmune
liver disease, iron overload) and those receiving treat-
ment with PPAR-γ agonists were not included in this
analysis. At the time of surgery, each patient underwent
a liver biopsy which was reviewed by the study patholo-
gist. In all cases, histological assessment of liver biopsies
had excluded NASH, thus the extent of NAFLD in all
cases was limited to steatosis of the liver. Diagnosis of
PCOS was established according to Rotterdam diagnosis
criteria and a combination of laboratory tests. Non-
PCOS causes of anovulation and infertility were ruled
out. In entire database, a total of 12 records satisfied
both non-NASH NAFLD and PCOS criteria outlined
above. These 12 records were further matched for age,
BMI, AST and ALT levels as well a number of other pa-
rameters with non-NASH NAFLD, non-PCOS subjects
form the same database. The ELISAs and qRT-PCR
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tients and matching. The study was approved by the In-
stitutional Review Board of Inova Fairfax Hospital
(Federal Assurance FWA00000573).
MRNA extraction
The total mRNAwas extracted from ~100 mg of frozen
adipose tissue samples using Aurum™ Total RNA Fatty
Acid and Fibrous Tissue Kit (Bio-Rad, Hercules, California)
as suggested by manufacturer. The quality of the
extracted mRNA was assessed spectrophotometrically
using the A260/A280 ratio that in all samples was be-
tween 1.8 and 2.0. In addition, the presence of intact
RNA was also confirmed electrophoretically at 1%
agarose gels with 28S and 18S rRNA bands clearly
visible and sharp.
First strand CDNA synthesis
Freshly extracted RNA samples were processed to
synthesize CDNA using RT2 First Strand Kit (Qiagen,
Valencia, CA). Reverse transcription reactions were
performed using approximately 1.5 μg of total RNA. Re-
actions were heated at 42°C for 5 min in a total volume
of 10.0 μl in the presence of 2.0 μl of 5X gDNA Elimin-
ation Buffer and chilled on ice immediately for at least
1 min. Then, a RT cocktail consisting of 4 μl of PC3 (5X
first strand buffer), 2 μl of RE3 (RT enzyme mix), 1 μl
P2 (Primer and External Control Mix) and 3 μl
nuclease-free H2O were added. The mixture was then
incubated at 42C for exactly 15 min and then immedi-
ately stopped by heating to 95 C for 5 minutes. 91 μl of
H2O was added to each 20-μl ofCDNA synthesis reac-
tion. All extracted RNAs and subsequent CDNA sam-
ples were stored in −20 C short-term and at −80 C
long-term.
Real- Time Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
Target genes for this study were selected among regula-
tory genes directly or indirectly involved in the insulin sig-
naling. Hence, the candidate genes were picked from the
carbohydrate metabolism pathway including: fructose-1,6-
bisphosphatase 1 (FBP1), glycogen synthase kinase-3β
interacting protein ninein (NIN) and protein phosphatase
1 (PPP1CA); from the lipid metabolism pathway: low
density lipoprotein receptor (LDLR), sterol regulatory
element binding transcription factor 1 (SREBF1), acetyl-
CoACarboxylase alpha (ACACA), sorbin and SH3 domain
containing 1 (SORBS1), RAF proto-oncogene serine/
threonine-protein kinase (RAF1); and target genes for per-
oxisome proliferator-activated receptor subfamily of nu-
clear receptors, such as acyl-CoA oxidase 1 (ACOX1) and
peroxisome proliferator-activated receptor gamma (PPARG).
For endogenous reference gene, we used RNA polymeraseII (RPII) that was validated in in previously published study
[19]. RPII was profiled simultaneously with each qRT-PCR
reaction.
PCR primers for ACTB, B2M, FBP1, NIN, PPP1CA,
LDLR, SREBF1, ACACA, RAF1, ACOX1, SORBS1 and
PPARG were purchased at Real Time Primers, USA.
Primers for the RPII and SORBS1 were custom designed
using Oligo Perfect Designer software (Invitrogen, USA)
and synthesized at Invitrogen, USA. Gene functions and
primer sequences are summarized in Table 1.
Gene expression levels were quantified by qRT-PCR
using the gene-specific primers with individual Tm’s be-
tween 58 C and 60 C. Primer specificity was validated by
both melting curve analysis and gel electrophoresis. The
real-time PCR mixtures containing 1 μl of the RT sam-
ple, 250 nM each of forward and reverse primers
(Quiagen, Valencia, CA) and 2X SsoFast™ EvaGreen®
Supermix (Bio-Rad Laboratories, Hercules, CA) were
carried out in a total volume of 10 μl. Reactions were
performed in a 96-well format in the BioRad CFX96 Real
Time System (BioRad Laboratories, Hercules, CA). After
melting curve based quality control, the RT-PCR data
were transformed using the ΔCt method.Enzyme-linked immunosorbent assay (ELISA)
Previously collected and frozen serum samples were
used to determine levels of the cytokines of interest by
96-well sandwich ELISA kits (Total CK18 and Caspase
Cleaved CK 18 Prototype - Peviva, Bromma, Sweden;
Human Adiponectin and Human Resistin – R&D Sys-
tems, Minneapolis, MN; Insulin EIA – Alpco Diagnosis,
Salem, NH). The detection limits forCK18 kits were: for
Total CK18 at 11 U/L, for caspase- cleaved CK18 at 5
U/L. For adipokine assays, the sensitivity limits were at
0.891 μg/mL for the adiponectin, at 0.055 ng/mL for the
resistin and at 0.399 μIU/mL for the insulin, as reported
by manufacturers. The optical densities (ODs) were
measured using the ELx800 spectrophotometer at
450 nm with a reference wavelength of 620 nm.Data analysis
To compare the expression levels of individual mRNAs,
the statistical analysis by non-parametric Mann–Whit-
ney test was performed. The analysis also included
Spearman rank correlation tests and multiple regression
analysis (MATLAB®, The MathWorks, Inc. Natick, MA).
P values < 0.05 were considered significant. The multiple
test corrections were carried out using Benjamini-
Hochberg-Yekutieli procedure that controls the false dis-
covery rate under positive dependence assumptions
reflecting known phenomenon of co-correlation of ex-
pression levels for genes involved in the same cellular or
organismal process. The procedure was executed using
Table 1 Sequences of primers used in qRT-PCR
Gene name Forward (F) Functions
Reverse (R)
Acetyl-CoACarboxylase Alpha (ACACA) 5′-CCCAGATTCTGCGTT TAAGA -3′ Long-chain fatty acid synthesis
5′-CATCCACATGT AAGCACCA -3′
Sterol Regulatory Element Binding Transcription Factor 1
(SREBF1)
5′-TACATTCGCTTTCTGCAACA -3′ Transcriptional activator for lipid
homeostasis
5′- GTCAGGTTCC TCCACCTC -3′
Peroxisome Proliferator-Activated Receptor Gamma (PPARG) 5′-CCC AAG TTT GAG TTT GCT GT -3′ Transcription factor
5′- AAC AGC TGT GAG GAC TCA GG3′
Glycogen Synthase Kinase 3 Beta interaction protein ninein (NIN) 5′- GAA TGT GGA TGG AGA GAT GC Glycogen metabolism
5′- ATT GCT GAT GAG GTT GTG GT 3′
RAF proto-oncogene serine/threonine-protein kinase (RAF1) 5′- ATCCGA ATGCAG GAT AAC AA 3′ Regulator inCell fate decisions
5′- AAG ATC TGG GGA GGC ATA TC3′
Fructose-1, 6-Bisphosphatase 1 (FBP1) 5′- TCA ACT GCT TCA TGC TGG AC -3′ Gluconeogenesis regulator
5′-CGT AGACCA GAG TGC GAT
GA3′
Acyl-CoA Oxidase 1 (ACOX1) 5′-CTG AAG GCT TTC ACC TCC TG -3′ Fatty acid Beta-Oxidation pathway
5′-CAT GCC ACACACCAACTT TC -3′
Low Density Lipoprotein Receptor (LDLR) 5′-CCA AACCCC TAA ACTCAG GA 3′ Receptor-mediated endocytosis of LDL
5′- AAG TGGCATCAT TTG GTG AA 3′
Sorbin and SH3 DomainContaining 1 (SORBS1) 5′-CTGCAAGCCCACAGTTTTCCAGT-3′ Insulin-stimulated glucose transport
5′-CGAGCAGCTTTCCTCCCCGC-3′
Protein phosphatase 1 (PPP1CA) 5′- ACC TGC AGTCTA TGG AGC AG 3′ Glycogen metabolism
5′- TAGCCG TCT TCT ACC ACC TG -3′
Table 2 Clinical and biochemical characteristics of PCOS-
NAFLD patients and controls
Non-PCOS (n = 12) PCOS (n = 12) p-value
Age, years 37.6 +/− 10.0 35.2 +/− 9.60 NS
Heights, cm 165.0 +/− 11.0 168.1 +/− 3.9 NS
Weight, kg 127.4 +/− 11.6 138.7 +/− 39.4 NS
BMI (kg/cm2) 44.1 +/− 3.9 45.0 +/− 3.6 NS
AST (U/L) 23.5 +/− 15.00 23.3 +/− 10.4 NS
ALT (U/L) 28.7 +/− 21.9 29.9 +/−15.3 NS
AST/ALT 0.96 +/− 0.35 0.85 +/− 0.24 NS
TCHOL (mg/dL) 187.3 +/− 31.2 178.5 +/− 34.9 NS
LDL (mg/dL) 101.4 +/− 27.5 108.1 +/−37.3 NS
HDL (mg/dL) 43.6 +/− 11.1 54.2 +/−14.6 NS
TRIG (mg/dL) 177.1 +/−110.52 133.7 +/−34.8 NS
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findings (after correction) were reported.
For co-correlated genes (ACACA, SREBF1, FBP1,
PPP1CA, ACOX1 and PPARG), the factor analysis was
performed with default rotation parameter and specified
single factor output. The estimates of factor loadings
were based on data from all subjects. The number of
factors was estimated using the maximum likelihood
method. The matrices of factor loadings were rotated by
orthogonal transformation to simplify the resulting
structure and ensure the independency of the factors.
The common factor obtained through this approach was
subject to a univariate correlation analyses with glucose
level, insulin level, individual adipokine levels and
HOMA scores.
Results
Clinical and biochemical characteristics of biopsy-proven
NAFLD patients with and without PCOS
For this study, we selected a set of biopsy-proven
NAFLD patients (N = 24) with (N = 12) or without
(N = 12) PCOS. In all cases, histological assessment of
liver biopsies had excluded NASH, thus the extent of
NAFLD in all cases was limited to steatosis of the liver.
NAFLD patients with PCOS and without PCOS werematched for age, BMI, AST and ALT levels as well a
number of other parameters (Table 2). Diagnosis of
PCOS was established according to Rotterdam diagnosis
criteria and a combination of laboratory tests. Non-
PCOS causes of anovulation and infertility were ruled
out. The clinical and biochemical descriptions are pro-
vided in Table 2.
Table 3 Adipokine and gene expression levels in PCOS-
NAFLD group and non-PCOS NAFLD
Non-PCOS (n = 12) PCOS (n = 12) P value
M65, U/L 284.18 +/− 73.81 299.92 +/− 98.87 NS
M30, U/L 119.07 +/− 7.94 224.93 +/− 111.87 < 0.03
Adiponectin, μg/ml 6.88 +/− 4.50 6.98 +/− 2.34 NS
Resistin, ng/ml 14.25 +/− 5.50 11.17 +/− 4.17 NS
Insulin (MicroIU/ml) 16.9 +/− 11.9 21.7 +/− 23.7 NS
ACACA 0.32 +/− 0.22 0.30 +/− 0.17 NS
SREBF1 0.56 +/− 0.43 0.67 +/− 0.35 NS
NIN 0.74 +/− 0.37 1.25 +/− 0.64 < 0.009
SORBS1 0.00173 +/− 0.00101 0.00216 +/− 0.00124 NS
FBP1 0.77 +/− 0.46 0.55 +/− 0.35 NS
PPP1CA 5.61 +/− 3.05 5.37 +/− 1.88 NS
RAF1 1.58 +/− 0.84 1.55 +/− 0.73 NS
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interacting protein ninein (NIN) and Low-density
lipoprotein receptor (LDLR) are altered in NAFLD + PCOS
group
To identify specificComponents of the insulin signaling
pathway that could potentially be involved in the patho-
genesis of PCOS in NAFLD patients, the expression
levels of ten target genes related to insulin regulation
were investigated: FBP1, NIN, PPP1CA, LDLR, SREBF1,
ACACA, RAF1, ACOX1, SORBS1 and PPARG.
Among these genes, expression levels of NIN and LDLR
mRNAs were significantly altered in the PCOS NAFLD
group as compared to the non-PCOS NAFLD group
(upregulated 1.65 fold with p < 0.009 and downregulated
0.51 fold with p < 0.04, respectively) (Figure 1). The gene ex-
pression levels for the rest of the target genes were not sig-
nificantly different between groups of patients (Table 3).ACOX1 3.82 +/− 3.91 3.66 +/− 3.27 NS
PPARG 8.96 +/− 8.29 10.56 +/− 10.49 NS
LDLR 0.45 +/− 0.38 0.21 +/− 0.16 < 0.042
Caspase cleaved CK18 levels are elevated significantly in
PCOS group
Since cell death is implicated in the pathogenesis of both
PCOS and NAFLD, we also compared the serum bio-
markers of cell death in both PCOS and non-PCOS
NAFLD patients. The serum total cytokeratin 18 (M65)
levels reflect the amount of total epithelial cell death, re-
gardless of the cause of death, the caspase cleaved
cytokeratin 18 (M30) is a biomarker of apoptosis. The
serum M65 levels in the PCOS NAFLD and the non-
PCOS-NAFLD groups were similar (Table 4), while the
levels of M30 were higher in PCOS–NAFLD group as
compared to that in the non PCOS-NAFLD groupFigure 1 Differential gene expression of NIN and LDLR genes in
PCOS and non-PCOS. (Fold change: 1.65, p = 0.009 and 0.51,
p = 0.042, respectively).
Table 4 Spearman correlation coefficients (r) with
p < 0.05
Correlating pair of the variables Correlation Coefficient
(r)
P value
Resistin - HOMA 0.66 < 0.0006
Resistin - Insulin 0.67 < 0.00005
Resistin - PT 0.42 < 0.045
LDLR - Resistin 0.721 < 0.0325
LDLR – PT 0.89 < 0.0076(224.93 U/L +/− 111.87 U/L vs. 119.07 U/L +/− 7.94 U/
L, P < 0.03) (Table 3 and Figure 2).
Resistin levels correlate with expression of LDLR and
measures of insulin resistance
The serum levels of resistin, adiponectin, and insulin
were not significantly different between NAFLD patients
with or without PCOS (Table 3). The levels of resistin
were positively correlated with expression levels of
LDLR, prothrombin time, serum levels of insulin and
HOMA scores. Additionally, levels of LDLR mRNA were
also correlated with prothrombin time (Table 4).
Levels of mRNAs encoding proteins involved in glucose
metabolism and lipid metabolism correlate with each
other
PPARG and ACOX1 proteins regulate of adipocyte dif-
ferentiation. Both of these proteins have been implicated
in both obesity and type 2 diabetes. In our study, expres-
sion levels of PPARG mRNA showed significant positive
correlation with levels of mRNAs encoded by genes involved
Figure 2 Caspase-cleavedCK18 (M30) levels in PCOS and
non-PCOS groups.
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esterol metabolism (SREBF1, r = 0.830, p < 0.006), glucose
metabolism (FBP1, r = 0.883, p < 0.003) and glycogen metab-
olism (PPP1CA, r = 0.700, p < 0.043 and ACOX1, r < 0.903,
p = 0.001). Expression levels for mRNAs of ACOX1,
SREBF1, FBP1, ACACA and PPP1CA genes wereCo-
correlated (Table 4). This co-correlation was observed in
both PCOS and non-PCOS groups and was confirmed by
factor analysis, where p-values for co-correlation to com-
mon factor varied from< 0.3 to < 1.56e-5. None of the other
measured parameters, including glucose, insulin, adipokine
levels and HOMA scores, were co-correlated to the expres-
sion levels for this group of genes.
Discussion
Recent studies have revealed that both PCOS and
NAFLD are strongly associated with insulin resistance,
metabolic syndrome and obesity [10]. This is especially
true for women with visceral obesity [3,4]. As women
with PCOS may be at increased risk for developing
NAFLD and conversely, women with NAFLD may be at
risk for PCOS, the screenings for these chronic and
inter-related diseases have been proposed in the respect-
ive cohorts [10]. Given the overlap in the pathogenesis,
molecular pathways involved in the pathogenesis of
these two different manifestations of metabolic syn-
drome will be of great interest.
In our previous study, we have shown that despite
similar clinical and laboratory profiles to the obese con-
trols, PCOS patients seem to be at increased risk for
histologic NASH [20]. In this study we specifically se-
lected the population of patients with both PCOS and
NAFLD that have not yet progressed to NASH
according to their liver biopsies (N = 12) and BMI-matched this population with non-PCOS non-NASH
NAFLD controls (N = 12). In fact, our results show that
levels of adiponectin, resistin, insulin and HOMA scores
as well as number of other clinical and biochemical pa-
rameters were not significantly different between these
two groups of patients (Table 2).
Nevertheless, we were able to show that level of
caspase-cleaved CK18 (M30) was significantly elevated
in PCOS patients with NAFLD, suggesting a more
prominent role for apoptosis in these patients. In fact,
this data indicate that presence of PCOS may indicate a
“more intense pro-apoptotic” environment. This obser-
vation confirms findings of Tan et al. who compared
serum apoptosis biomarkers in 186 PCOS patients and
73 age-matched controls, and found that M30 levels are
higher in PCOS patients than in normal controls even
after correction for BMI and suggested that NASH
should be prevalent in PCOS cohorts [21]. However, our
study takes this investigation one step further, as its de-
sign specifically excluded patients with histologically
confirmed NASH, thus indicating that an increase in
apoptosis is an early feature of NAFLD observed in
PCOS subjects, or that an overall increase in apoptosis
is a general feature of PCOS. One of the most prominent
features of PCOS is a hyperproduction of androgens, like
testosterone, dihydrotestosterone (DHT) and dehydro-
epiandrosterone (DHEA). Androgens are known as
proapotototic agents and were shown to act upon many
types of peripheral cells, including hepatocytes [22]. For
example, DHT administration results in apoptosis of
androgen-sensitive liver cells, that is, at least in part, re-
alized through PKR/eIF2α/GADD153 cascades [22]. It is
possible that the patients with concomitant NAFLD are
more prone to the development of NASH, as androgen-
instigated apoptotic processes in their livers actively con-
tribute to the progression of NAFLD. To further investigate
this hypothesis, the study of larger cohorts of PCOS pa-
tients are needed, including subgroups without any histo-
logical sign of the liver disease and those without an excess
of androgens.
Our present study also provides interesting insights
into the PCOS-associated changes in the expression
levels of genes involved in specific aspects of the lipid
metabolism and theCarbohydrate metabolism in adipose.
Importantly, in adipose tissue specimen collected from
PCOS patients, decreased mRNA levels for LDL recep-
tor (LDLR) were observed. The expression of LDLR gene
is a subject of estrogen control that is maintained
through the estrogen-responsive region adjacent to the
sterol response element within the LDLR promoter. In
addition, in hepatocytes, androgen receptor agonists
were shown to attenuate the estrogen-induced up-
regulation of LDLR [23]. It seems that hyperandrogenic
phenotype of PCOS may have a direct suppressive
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and in the liver. As the LDL receptor plays a major role
in the clearance of apoB and apoE-containing lipopro-
teins, its downregulation should prolong the plasma
half-life of VLDL and LDL and, therefore, have
steatogenic effects. In accordance with this logic, Ldlr
−/− mice have increased sensitivity for oxLDL-induced
inflammation, apoptosis and fibrosis [24]. On diabeto-
genic, cholesterol-augmented diet, Ldlr−/c mice develop
a distinct hepatic phenotype characterized by increased
inflammation and oxidative stress [25]. Thus, an ob-
served decrease in LDLR mRNA in PCOS might be
connected to the proneness of PCOS patients with con-
comitant liver disease to the progression to NASH.
The only other mRNA that was differentially expressed in
PCOS adipose tissue was one encoding for centrosomal pro-
tein ninein (NIN). NIN was selected for this study as it inter-
acts with kinase GSK3beta that is hyperactivated and
resistant to down-regulation by insulin in adipocytes of
women with PCOS [26]. As of now, the connection of the
ninein to PCOS phenotype is unclear. One possible clue that
can make this connection is that the ninein is critical for the
formation of vascular tubes [27]. An observed increase in
the expression of ninein aligns well with hypervascularity of
the ovarian theca interna and stroma commonly observed
in patients with PCOS [28].
When PCOS and non-PCOS NAFLD groups were
compared, no difference in the levels of resistin,
adiponectin and insulin were observed, thus, confirming
the findings of others [29,30] and pointing to the fact
that the levels of these hormones are defined by under-
lying metabolic states and patient’s BMI, rather than by
PCOS. On the other hand, when the entire group of
NAFLD patients was analyzed together, the levels of
LDLR mRNA expression in adipose were positively
correlated with serum levels of resistin. This is an im-
portant observation as resistin was recently shown to
downregulate LDLR at the protein level in vitro, both in
HepG2 and in primary hepatocytes, through an increase
in cellular expression of the recently identified protease,
PCSK9, which enhances intracellular LDLR lysosomal
degradation [31]. Thus, our study indicates that the
same phenomenon may take place in vivo, and highlighs
resistin as a possible therapeutic target to be manipu-
lated in patients with elevated serum LDL levels.
Additionally, both LDLR mRNA expression and resistin
levels were correlated with the measure of the extrinsic
pathway of coagulation, prothrombin time (PT). An in-
crease in PT is common in insulin resistance and in PCOS
that are both regarded as low-grade systemic coagulation
conditions [32,33]. Recenty, resistin was shown to induce a
procoagulant state in HUVECs by inducing both the ex-
pression of tissue factor (TF) and the activity of factor Xa
[34]. Correlative observations made in metabolic syndromecohorts showed that resistin is strongly associated with
hypercoagulative and hypofibrinolitic activities [35]. It
seems that inflammation-associated increases in the release
of resistin into circulation might contribute to the
prothrombotic state observed under diabetic conditions.
The limitation of our study, as with most molecular
studies, is small sample size, which may contribute to
the lack of statistically significant differences of group
comparison analysis of changes in gene expressions as
well as limit our analysis of correlations. However, in
our design we attempted the mitigation of these limita-
tions by matching the PCOS and non-PCOS groups of
study subjects by age, BMI and liver enzyme as well as
the histology of their liver. We hope that the findings of
our study will aids in untangling complex relationship
between NAFLD and PCOS, and point toward novel av-
enues for similarly designed studies in larger cohorts.
Conclusion
In conclusion, we report that the total serum levels of apop-
totic biomarker M30 are significantly elevated in PCOS pa-
tients with liver steatosis as compared to non-PCOS
NAFLD controls, suggesting that an androgen-dependent
proapoptotic PCOS environment may directly contribute
to NAFLD progression in these patients. Similarly,
hyperandrogenism may explain an observed decrease in
adipose LDLR mRNA expression that may be connected to
the proneness of PCOS patients with concomitant liver dis-
ease to the progression to NASH. Additionally, our study
suggests that inflammation-associated increase in the re-
lease of resistin into circulation might contribute to the
prothrombotic state observed under conditions associated
with insulin resistance, including PCOS.
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